Other Corporate Information

• 28 Jun, 2023
  Spago Nanomedical uppdaterar om den kliniska fas IIa-studien SPAGOPIX-02
• 28 Jun, 2023
  Spago Nanomedical updates on the clinical phase IIa study SPAGOPIX-02
• 13 Jun, 2023
  Spago Nanomedical stärker Tumorad® genom nytt vetenskapligt råd
• 13 Jun, 2023
  Spago Nanomedical strengthens Tumorad® by establishment of Scientific Advisory Board
• 23 May, 2023
  Spago Nanomedical has submitted application to start Tumorad® clinical phase I/IIa study
• 23 May, 2023
  Spago Nanomedical har lämnat in ansökan om att starta klinisk fas I/IIa-studie med Tumorad®
• 4 May, 2023
  Presentation av Spago Nanomedicals kliniska fas IIa-studie i endometrios vid 15th World Congress of Endometriosis
• 4 May, 2023
  Presentation of Spago Nanomedical’s clinical phase IIa study in endometriosis at the 15th World Congress of Endometriosis
• 4 Apr, 2023
  The nomination committee proposes changes to the board of Spago Nanomedical for increased commercial focus
• 4 Apr, 2023
  Valberedningen föreslår förändringar i styrelsen för Spago Nanomedical för ökat kommersiellt fokus